Drug Profile
Research programme: fms-like tyrosine kinase 3 inhibitors - Kyowa Kirin
Latest Information Update: 16 Jul 2019
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Developer Kyowa Kirin
- Class Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Japan (PO)
- 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin
- 16 Apr 2008 Preclinical trials in Acute myeloid leukaemia in Japan (PO)